MADRIGAL PHARMACEUTICALS INC
For the period ended Mar 31, 2025. Filed May 1, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 1, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Director and Executive Officer 10b5-1 Plans
Our policy governing transactions in our securities by our directors, officers and employees permits our directors, officers and employees to enter into trading plans complying with Rule 10b5-1 under the Exchange Act. The following table describes the written plans for the sale of our securities that were adopted by our executive officers and directors during the quarter ended March 31, 2025. Each of the plans was entered into during an open trading window and is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) (each a “Trading Plan”).
| Name and Title | Action Taken (Date) | Scheduled Start Date of Trading Plan | Scheduled Expiration Date of Trading Plan | Maximum Number of Shares Subject to Trading Plan |
|---|---|---|---|---|
| Paul Friedman, M.D., Director | Adoption (March 14, 2025) | June 13, 2025 | July 22, 2026 | 206,256 |
| Rebecca Taub, M.D., Senior Scientific and Medical Advisor and Director | Adoption (March 14, 2025) | June 13, 2025 | July 22, 2026 | 76,564 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.